ABSTRACT
Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.
Subject(s)
Diabetes Mellitus, Type 2 , Hyperglycemia , Humans , Hypoglycemic Agents/therapeutic use , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/complications , Hyperglycemia/drug therapy , Blood GlucoseABSTRACT
This Guideline represents the recommendations of the Austrian Diabetes Association (ÖDG) on the use of diabetes technology (insulin pump therapy; continuous glucose monitoring, CGM; hybrid closed-loop systems, HCL; diabetes apps) and access to these technological innovations for people with diabetes mellitus based on current scientific evidence.
Subject(s)
Diabetes Mellitus, Type 1 , Humans , Diabetes Mellitus, Type 1/drug therapy , Insulin/therapeutic use , Blood Glucose , Blood Glucose Self-Monitoring , Insulin Infusion Systems , Hypoglycemic Agents/therapeutic useABSTRACT
This position statement is based on current evidence available on the safety and benefits of continuous subcutaneous insulin infusion therapy (CSII, pump therapy) in diabetes with an emphasis on the effects of CSII on glycemic control, hypoglycaemia rates, occurrence of ketoacidosis, quality of life and the use of insulin pump therapy in pregnancy. The current article represents the recommendations of the Austrian Diabetes Association for the clinical praxis of insulin pump treatment in children, adolescents and adults.
Subject(s)
Diabetes Mellitus, Type 1 , Hypoglycemic Agents/therapeutic use , Insulin Infusion Systems , Quality of Life , Adolescent , Adult , Austria , Child , Diabetes Mellitus, Type 1/drug therapy , Female , Humans , Hypoglycemic Agents/administration & dosage , Infusion Pumps, Implantable , Insulin , Male , Practice Guidelines as TopicABSTRACT
The present article is a recommendation of the Austrian Diabetes Association for the practical use of insulin in type 2 diabetes, including the various insulin regimens.
Subject(s)
Diabetes Mellitus, Type 2 , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Practice Guidelines as Topic , Austria , Diabetes Mellitus, Type 2/drug therapy , Dose-Response Relationship, Drug , Drug Administration Schedule , HumansABSTRACT
Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.
Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 2 , Hypoglycemic Agents/therapeutic use , Practice Guidelines as Topic , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/drug therapy , Humans , Hyperglycemia/drug therapy , Life StyleABSTRACT
This position statement represents the recommendations of the Austrian Diabetes Association regarding the clinical diagnostic and therapeutic application, safety and benefits of continuous subcutaneous glucose monitoring systems in patients with diabetes, based on current evidence.
Subject(s)
Blood Glucose Self-Monitoring , Blood Glucose/analysis , Diabetes Mellitus/blood , Diabetes Mellitus/diagnosis , Austria , Blood Glucose Self-Monitoring/instrumentation , Blood Glucose Self-Monitoring/methods , Blood Glucose Self-Monitoring/standards , Diabetes Mellitus/therapy , Humans , Insulin , Monitoring, Ambulatory , Practice Guidelines as TopicABSTRACT
Exocrine pancreatic insufficiency (EPI) in diabetic patients is frequent. Studies based on fecal elastase-1 measurement give prevalence rates of 10â30 % of severe and 22â56 % of moderate EPI in type 1 and rates of 5â46 % in type 2 diabetic patients. Nevertheless, not all patients report typical symptoms like diarrhea, steatorrhea and weight loss. For noninvasive testing the determination of fecal elastase-1 has the highest sensitivity and specificity. This test should be performed at least in all symptomatic patients. As differential diagnosis celiac disease (with a prevalence of about 3-5 % of type 1 diabetic patients), autonomic neuropathy, but also diseases like irritable bowel syndrome and gastrointestinal tumors have to be taken into account. Patients with symptoms and a fecal elastase-1 < 100 µg/g should be treated with pancreatic enzymes in adequate daily doses administered at main meals. Treatment improves symptoms significantly, supply with fat soluble vitamins is normalised, risk for osteoporosis is reduced. However, improvement of glucose metabolism has not been demonstrated consistently. A pancreatogenic diabetes, also termed as type 3c diabetes, has not necessarily to be treated with insulin, often-at least initially-treatment with oral antidiabetic drugs is sufficient.
Subject(s)
Diabetes Mellitus/diagnosis , Diabetes Mellitus/therapy , Endocrinology/standards , Exocrine Pancreatic Insufficiency/diagnosis , Exocrine Pancreatic Insufficiency/therapy , Practice Guidelines as Topic , Austria/epidemiology , Comorbidity , Diabetes Mellitus/epidemiology , Evidence-Based Medicine , Exocrine Pancreatic Insufficiency/epidemiology , Humans , Prevalence , Risk Factors , Treatment OutcomeABSTRACT
This position statement represents the recommendations of the Austrian Diabetes Association regarding the clinical diagnostic and therapeutic application, safety and benefits of continuous subcutaneous glucose monitoring systems in patients with diabetes mellitus, based on current evidence.
Subject(s)
Blood Glucose Self-Monitoring/standards , Blood Glucose/analysis , Diabetes Mellitus/blood , Diabetes Mellitus/therapy , Patient Education as Topic/standards , Practice Guidelines as Topic , Austria , Diabetes Mellitus/diagnosis , Evidence-Based Medicine , Humans , Monitoring, Ambulatory/standards , Patient ComplianceABSTRACT
This position statement is based on the current evidence available on the safety and benefits of continuous subcutaneous insulin pump therapy (CSII) in diabetes with an emphasis on the effects of CSII on glycemic control, hypoglycaemia rates, occurrence of ketoacidosis, quality of life and the use of insulin pump therapy in pregnancy. The current article represents the recommendations of the Austrian Diabetes Association for the clinical praxis of insulin pump treatment in children, adolescents and adults.
Subject(s)
Diabetes Mellitus/diagnosis , Diabetes Mellitus/drug therapy , Drug Monitoring/standards , Insulin Infusion Systems/standards , Insulin/administration & dosage , Practice Guidelines as Topic , Adolescent , Adult , Austria , Child , Child, Preschool , Diabetes Mellitus/psychology , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Monitoring/psychology , Evidence-Based Medicine , Female , Humans , Hypoglycemic Agents/administration & dosage , Insulin Infusion Systems/psychology , Male , Quality of Life/psychology , Treatment Outcome , Young AdultABSTRACT
This position statement is based on the cur-rent evidence available on the safety and benefits of continous subcutaneous insulin pump therapy (CSII) in diabetes mellitus with an emphasis on the effects of CSII on glycemic control, hypoglycaemia rates, occur-ance of ketoacidosis, quality of life and the use of insu-lin pump therapy in pregnancy. The current article rep-resents the recommendations of the Austrian Diabetes Association for the clinical praxis of insulin pump treat-ment in children and adults.
